BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BSX - US1011371077 - Common Stock
84.4 EUR
+3.6 (+4.46%)
Overall BSX gets a fundamental rating of 5 out of 10. We evaluated BSX against 65 industry peers in the Health Care Equipment & Supplies industry. BSX has an average financial health and profitability rating. BSX shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year BSX was profitable.
BSX had a positive operating cash flow in the past year.
BSX had positive earnings in 4 of the past 5 years.
In the past 5 years BSX always reported a positive cash flow from operatings.
1.2 Ratios
BSX's Return On Assets of 6.54% is fine compared to the rest of the industry. BSX outperforms 67.69% of its industry peers.
With a decent Return On Equity value of 11.93%, BSX is doing good in the industry, outperforming 67.69% of the companies in the same industry.
BSX's Return On Invested Capital of 8.09% is fine compared to the rest of the industry. BSX outperforms 66.15% of its industry peers.
BSX had an Average Return On Invested Capital over the past 3 years of 6.59%. This is below the industry average of 10.04%.
The last Return On Invested Capital (8.09%) for BSX is above the 3 year average (6.59%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROIC | 8.09% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
1.3 Margins
BSX has a better Profit Margin (14.42%) than 80.00% of its industry peers.
BSX's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 19.40%, BSX belongs to the best of the industry, outperforming 81.54% of the companies in the same industry.
BSX's Operating Margin has been stable in the last couple of years.
With a decent Gross Margin value of 68.57%, BSX is doing good in the industry, outperforming 73.85% of the companies in the same industry.
In the last couple of years the Gross Margin of BSX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% |
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BSX is destroying value.
The number of shares outstanding for BSX has been increased compared to 1 year ago.
Compared to 5 years ago, BSX has more shares outstanding
BSX has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.52 indicates that BSX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 5.52, BSX belongs to the best of the industry, outperforming 87.69% of the companies in the same industry.
The Debt to FCF ratio of BSX is 3.03, which is a good value as it means it would take BSX, 3.03 years of fcf income to pay off all of its debts.
BSX's Debt to FCF ratio of 3.03 is fine compared to the rest of the industry. BSX outperforms 69.23% of its industry peers.
BSX has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of BSX (0.48) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 5.52 |
ROIC/WACC0.85
WACC9.55%
2.3 Liquidity
A Current Ratio of 1.51 indicates that BSX should not have too much problems paying its short term obligations.
BSX has a Current ratio (1.51) which is comparable to the rest of the industry.
A Quick Ratio of 0.96 indicates that BSX may have some problems paying its short term obligations.
BSX has a Quick ratio of 0.96. This is in the lower half of the industry: BSX underperforms 61.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.00% over the past year.
BSX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.56% yearly.
BSX shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.62%.
The Revenue has been growing by 9.30% on average over the past years. This is quite good.
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
3.2 Future
BSX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.01% yearly.
The Revenue is expected to grow by 12.51% on average over the next years. This is quite good.
EPS Next Y22.13%
EPS Next 2Y18.12%
EPS Next 3Y16.5%
EPS Next 5Y15.01%
Revenue Next Year20.9%
Revenue Next 2Y16.08%
Revenue Next 3Y14.18%
Revenue Next 5Y12.51%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BSX is valuated quite expensively with a Price/Earnings ratio of 33.49.
BSX's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of BSX to the average of the S&P500 Index (26.92), we can say BSX is valued slightly more expensively.
A Price/Forward Earnings ratio of 28.16 indicates a quite expensive valuation of BSX.
BSX's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.57, BSX is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.49 | ||
| Fwd PE | 28.16 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BSX indicates a slightly more expensive valuation: BSX is more expensive than 61.54% of the companies listed in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as BSX.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 38.24 | ||
| EV/EBITDA | 30.66 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
BSX has a very decent profitability rating, which may justify a higher PE ratio.
BSX's earnings are expected to grow with 16.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.51
PEG (5Y)3.5
EPS Next 2Y18.12%
EPS Next 3Y16.5%
5. Dividend
5.1 Amount
BSX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:BSX (1/7/2026, 7:00:00 PM)
84.4
+3.6 (+4.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners94.07%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap125.12B
Revenue(TTM)19.35B
Net Income(TTM)2.79B
Analysts86
Price Target109.09 (29.25%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.27%
Min EPS beat(2)2.49%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)5.68%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.15%
EPS beat(12)12
Avg EPS beat(12)5.77%
EPS beat(16)15
Avg EPS beat(16)4.37%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)1.6%
Min Revenue beat(4)0.96%
Max Revenue beat(4)2.43%
Revenue beat(8)8
Avg Revenue beat(8)2.16%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.61%
PT rev (1m)-1.85%
PT rev (3m)0.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.36%
EPS NY rev (1m)0.01%
EPS NY rev (3m)1.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.17%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.49 | ||
| Fwd PE | 28.16 | ||
| P/S | 7.55 | ||
| P/FCF | 38.24 | ||
| P/OCF | 31.61 | ||
| P/B | 6.25 | ||
| P/tB | N/A | ||
| EV/EBITDA | 30.66 |
EPS(TTM)2.52
EY2.99%
EPS(NY)3
Fwd EY3.55%
FCF(TTM)2.21
FCFY2.62%
OCF(TTM)2.67
OCFY3.16%
SpS11.17
BVpS13.51
TBVpS-1.14
PEG (NY)1.51
PEG (5Y)3.5
Graham Number27.67
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROCE | 10.04% | ||
| ROIC | 8.09% | ||
| ROICexc | 8.38% | ||
| ROICexgc | 28.19% | ||
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% | ||
| FCFM | 19.76% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
ROICexc(3y)6.75%
ROICexc(5y)5.93%
ROICexgc(3y)22.84%
ROICexgc(5y)19.53%
ROCE(3y)8.18%
ROCE(5y)7.08%
ROICexgc growth 3Y9.18%
ROICexgc growth 5Y7.17%
ROICexc growth 3Y4.96%
ROICexc growth 5Y5.6%
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
F-Score6
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.18 | ||
| Cap/Depr | 59.36% | ||
| Cap/Sales | 4.14% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 90.6% | ||
| Profit Quality | 136.98% | ||
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 | ||
| Altman-Z | 5.52 |
F-Score6
WACC9.55%
ROIC/WACC0.85
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
EPS Next Y22.13%
EPS Next 2Y18.12%
EPS Next 3Y16.5%
EPS Next 5Y15.01%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
Revenue Next Year20.9%
Revenue Next 2Y16.08%
Revenue Next 3Y14.18%
Revenue Next 5Y12.51%
EBIT growth 1Y30.66%
EBIT growth 3Y13.12%
EBIT growth 5Y10.92%
EBIT Next Year37.61%
EBIT Next 3Y20.84%
EBIT Next 5Y17.37%
FCF growth 1Y125.15%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y96.47%
OCF growth 3Y22.44%
OCF growth 5Y13.34%
BOSTON SCIENTIFIC CORP / BSX.DE FAQ
What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSX.DE.
What is the valuation status for BSX stock?
ChartMill assigns a valuation rating of 2 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Overvalued.
How profitable is BOSTON SCIENTIFIC CORP (BSX.DE) stock?
BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 7 / 10.
What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX.DE) is 33.49 and the Price/Book (PB) ratio is 6.25.
Can you provide the expected EPS growth for BSX stock?
The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX.DE) is expected to grow by 22.13% in the next year.